Targeting cyclooxygenase enzyme for the adjuvant COVID‐19 therapy.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 469, doi. 10.1002/ddr.21794
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2021 AND VI 82 AND IP 4
Results: 15
1
2
Neuroprotective mechanisms of mangiferin in neurodegenerative diseases.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 494, doi. 10.1002/ddr.21783
- By:
- Publication type:
- Article
3
Overview of in situ gelling injectable hydrogels for diabetic wounds.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 503, doi. 10.1002/ddr.21788
- By:
- Publication type:
- Article
4
Design, synthesis, molecular docking, anti‐quorum sensing, and anti‐biofilm activity of pyochelin‐zingerone conjugate.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 605, doi. 10.1002/ddr.21781
- By:
- Publication type:
- Article
5
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 598, doi. 10.1002/ddr.21780
- By:
- Publication type:
- Article
6
Targeting AGE‐RAGE signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 589, doi. 10.1002/ddr.21779
- By:
- Publication type:
- Article
7
Cryptotanshinone ameliorates cardiac injury and cardiomyocyte apoptosis in rats with coronary microembolization.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 581, doi. 10.1002/ddr.21777
- By:
- Publication type:
- Article
8
Oridonin alleviates d‐GalN/LPS‐induced acute liver injury by inhibiting NLRP3 inflammasome.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 575, doi. 10.1002/ddr.21776
- By:
- Publication type:
- Article
9
Macrocyclic sulfone derivatives: Synthesis, characterization, in vitro biological evaluation and molecular docking.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 562, doi. 10.1002/ddr.21775
- By:
- Publication type:
- Article
10
Hirudin prevents vascular endothelial cell apoptosis and permeability enhancement induced by the serum from rat with chronic renal failure through inhibiting RhoA/ROCK signaling pathway.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 553, doi. 10.1002/ddr.21773
- By:
- Publication type:
- Article
11
Issue Information.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 467, doi. 10.1002/ddr.21693
- Publication type:
- Article
12
Design, synthesis, in vitro and in silico studies of novel Schiff base derivatives of 2‐hydroxy‐4‐methoxybenzamide as tyrosinase inhibitors.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 533, doi. 10.1002/ddr.21771
- By:
- Publication type:
- Article
13
Marein ameliorates Ang II/hypoxia‐induced abnormal glucolipid metabolism by modulating the HIF‐1α/PPARα/γ pathway in H9c2 cells.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 523, doi. 10.1002/ddr.21770
- By:
- Publication type:
- Article
14
Review of registered clinical trials for the treatment of COVID‐19.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 474, doi. 10.1002/ddr.21762
- By:
- Publication type:
- Article
15
Synergistic protective effects between docosahexaenoic acid and omeprazole on the gastrointestinal tract in the indomethacin‐induced injury model.
- Published in:
- Drug Development Research, 2021, v. 82, n. 4, p. 543, doi. 10.1002/ddr.21772
- By:
- Publication type:
- Article